

Literatur

1. Durosaro O et al (2009) Incidence of cutaneous lupus erythematosus, 1965–2005: a population-based study. *Arch Dermatol* 145:249–253
2. Jarukitsopa S et al (2015) Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States. *Arthritis Care Res* 67:817–828
3. Wenzel J et al (2005) Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. *Br J Dermatol* 153:1011–1015
4. Grassi M, Capello F, Bertolino L, Seia Z, Pippione M (2009) Identification of granzyme B-expressing CD-8-positive T cells in lymphocytic inflammatory infiltrate in cutaneous lupus erythematosus and in dermatomyositis. *Clin Exp Dermatol* 34:910–914
5. Reich A, Meurer M, Viehweg A, Muller DJ (2009) Narrow-band UVB-induced externalization of selected nuclear antigens in keratinocytes: implications for lupus erythematosus pathogenesis. *Photochem Photobiol* 85:1–7
6. Scholtissek B et al (2017) Immunostimulatory endogenous nucleic acids drive the lesional inflammation in cutaneous lupus erythematosus. *J Invest Dermatol* 137:1484–1492
7. Sarkar MK et al (2018) Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa. *Ann Rheum Dis* 77:1653–1664
8. Zhang Y-P, Wu J, Han Y-F, Shi Z-R, Wang L (2017) Pathogenesis of cutaneous lupus erythema associated with and without systemic lupus erythema. *Autoimmun Rev* 16:735–742
9. Zahn S et al (2011) Evidence for apathophysiological role of keratinocyte-derived type III interferon (IFN λ) in cutaneous lupus erythematosus. *J Invest Dermatol* 131:133–140
10. Wenzel J et al (2005) Enhanced type I interferon signaling promotes Th1-biased inflammation in cutaneous lupus erythematosus. *J Pathol* 205:435–442
11. Lauffer F et al (2018) Type I immune response induces keratinocyte necroptosis and is associated with interface dermatitis. *J Invest Dermatol* 38:1785–1794
12. Farkas L et al (2001) Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. *Am J Pathol* 159:237–243
13. Safi R et al (2019) Investigating the presence of neutrophil extracellular traps in cutaneous lesions of different subtypes of lupus erythematosus. *Exp Dermatol* 28:1348–1352
14. Whitacre CC (2001) Sex differences in autoimmune disease. *Nat Immunol* 2:777–780
15. Durosaro O et al (2009) Incidence of cutaneous lupus erythematosus, 1965–2005: a population-based study. *Arch Dermatol* 145:249–253
16. Khan D, Ansar Ahmed S (2016) The immune system is a natural target for estrogen action: opposing effects of estrogen in two prototypical autoimmune diseases. *Front Immunol* 6:635
17. Hersh AO, Arkin LM, Prahalad S (2016) Immunogenetics of cutaneous lupus erythematosus. *Curr Opin Pediatr* 28:470–475
18. Peschke K et al (2014) Deregulated type I IFN response in TREX1-associated familial chilblain lupus. *J Invest Dermatol* 134:1456–1459
19. Ravenscroft JC et al (2011) Autosomal dominant inheritance of a heterozygous mutation in SAMHD1 causing familial chilblain lupus. *Am J Med Genet A* 155A:235–237
20. König N et al (2017) Familial chilblain lupus due to again-of-function mutation in STING. *Ann Rheum Dis* 76:468–472
21. Kuhn A et al (2014) Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database. *Br J Dermatol* 171:571–579
22. Vaglio A et al (2018) Drug-induced lupus: traditional and new concepts. *Autoimmun Rev* 17:912–918
23. Shovman O et al (2018) Diverse patterns of anti-TNF- α -induced lupus: case series and review of the literature. *Clin Rheumatol* 37:563–568
24. Levine D et al (2010) Cutaneous lupus erythematosus and anti-TNF- α therapy: a case report with review of the literature. *J Drugs Dermatol* 9:1283–1287
25. Quaglia M et al (2021) Viral infections and systemic lupus erythematosus: new players in an old story. *Viruses* 13:277
26. Battaglia M, Garrett-Sinha LA (2020) Bacterial infections in lupus: roles in promoting immune activation and in pathogenesis of the disease. *J Transl Autoimmun* 4:100078
27. Fernandez-Ruiz R et al (2020) COVID-19 inpatients with systemic lupus erythematosus: lessons learned from the inflammatory disease. *Transl Res* 232:13–36
28. Cornelius R, Pawlak CR et al (2003) Flares in patients with systemic lupus erythematosus are associated with daily psychological stress. *Psychother Psychosom* 72:159–165
29. Sontheimer RD (1997) The lexicon of cutaneous lupus erythematosus – A review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus. *Lupus* 6:84–95
30. Kuhn A, Landmann A (2014) The classification and diagnosis of cutaneous lupus erythematosus. *J Autoimmun* 48–49:14–19
31. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 40:1725
32. Aringer M et al (2019) 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Arthritis Rheumatol* 71:1400–1412
33. Kuhn A et al (2010) Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. *Br J Dermatol* 163:83–92
34. AWMF (2020) S2k-Leitlinie „Diagnostik und Therapie des kutanen Lupus erythematoses“ (AWMF-Registernummer 013-060)
35. Roenigk HH et al (1980) Discoid lupus erythematosus: diagnostic features and evaluation of topical corticosteroid therapy. *Cutis* 25:281–285
36. Tzung TY et al (2007) Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study. *Br J Dermatol* 156:191–192
37. Tlacuilo-Parra A et al (2005) Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. *Rheumatology (Oxford)* 44:1564–1568
38. Yokogawa N et al (2017) Effects of Hydroxychloroquine in patients with cutaneous lupus erythematosus: a multicenter, double-blind, randomized, parallel-group trial. *Arthritis Rheumatol* 69:791–799
39. Borik L et al (2019) Type IV allergy to antimalarials can mimic cutaneous manifestations of lupus erythematosus. *J Eur Acad Dermatol Venereol* 33:e94–e96
40. Chasset F, Frances C, Barete S, Amoura Z, Arnaud L (2015) Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. *J Am Acad Dermatol* 72:634–639
41. Wenzel J, Braehler S, Bauer R, Bieber T, Tuting T (2005) Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. *Br J Dermatol* 153:157–162
42. Ruzicka T et al (1992) Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. *Br J Dermatol* 127:513–518
43. Klebes M et al (2016) Dapsone as second-line treatment for cutaneous lupus erythematosus? A retrospective analysis of 34 patients and a review of the literature. *Dermatology* 232:91–96
44. Sadlier M et al (2012) Mycophenolate mofetil and hydroxychloroquine: an effective treatment for recalcitrant cutaneous lupus erythematosus. *J Am Acad Dermatol* 66:160–161
45. Chasset F, Tounsi T, Cesbron E, Barbaud A, Frances C, Arnaud L (2018) Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: a systematic review and meta-analysis. *J Am Acad Dermatol* 78:342–350.e4
46. Callen JP, Spencer LV, Burruss JB, Holtman J (1991) Azathioprine. An effective, corticosteroid-sparing therapy for patients

with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. *Arch Dermatol* 127:515–522

47. Salle R et al (2020) Belimumab for refractory manifestations of cutaneous lupus: a multicenter, retrospective observational study of 16 patients. *J Am Acad Dermatol* 83:1816–1819
48. Quelhas da Costa R et al (2018) Assessment of response to B-cell depletion using rituximab in cutaneous lupus erythematosus. *JAMA Dermatol* 154:1432–1440
49. Brucato A et al (2001) Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. *Arthritis Rheum* 44:1832–1835
50. Izmirly PM et al (2011) Maternal and fetal factors associated with mortality and morbidity in a multiracial/ethnic registry of anti-SSA/Ro associated cardiac neonatal lupus. *Circulation* 124:1927–1935
51. Brooks P (2015) Fetal manifestations of maternal anti-Ro and La antibodies – more than complete heart block. *Australas J Ultrasound Med* 18:124–128
52. Miyakata S et al (2001) Therapeutic plasmapheresis for the prevention of congenital complete heart block associated with anti-SS-A/Ro antibody and anti-SS-B/La antibody. *Ryumachi* 41:726–735
53. Sammaritano LR et al (2020) 2020 American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. *Arthritis Care Res (Hoboken)* 72:461–488